PROTAC R&D Service Platform
Targeted protein degradation therapeutics
Proteolysis targeting chimeras (PROTACs) offer a fast and reversible chemical knock-down approach to control protein function. PROTAC technology takes advantage of a moiety of targeted protein and a moiety of recognizing E3 ubiquitin ligase and produces a hybrid molecule to specifically knock down a targeted protein.
Medicilon provides PROTAC drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services. Medicilon’s PROTAC drug discovery technology platform covers the currently popular target protein ligands. We have established a linker system with an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize a substantial amount of highly active PROTAC bispecific small molecules, which would have the potential to significantly facilitate the drug discovery and development process.
As of the end of June 2023, Medicilon has successfully assisted in the clinical approval of 5 PROTAC drugs (1 approved by FDA and NMPA) and has 20+ PROTAC projects under development.